A North Wales cancer patient has become the first in the world to take part in a new trial looking for a more effective treatment for myeloma. The study compares two different combinations of cancer medicines to see which helps control myeloma better in patients whose disease is no longer responding to treatment, or whose...Continue Reading

A multidisciplinary team of researchers from the National University of Singapore (NUS) has developed an artificial intelligence (AI) technology platform that could potentially change the way drug combinations are being designed, hence enabling doctors to determine the most effective drug combination for a patient quickly. Applying the platform towards drug resistant multiple myeloma, a type...Continue Reading

A group of “real-world” patients with relapsed or refractory multiple myeloma had high response rates and an overall survival (OS) of about 3 years when treated with bortezomib-based therapy, according to results of the electronic Velcade Observational Study (eVOBs). “While the benefits of bortezomib-based therapy have been exemplified in clinical trials, use of bortezomib for...Continue Reading